Back to results
US 5,908,773 AGranted
KSHV positive cell lines
AssigneeCornell Research Foundation, Inc.
InventorsEthel Cesarman, Leandros Arvanitakis, Daniel M. Knowles, Enrique Mesri
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCornell Research Foundation, Inc.
InventorsEthel Cesarman, Leandros Arvanitakis, Daniel M. Knowles, Enrique Mesri
Estimating the term…
The invention provides a cell line comprising Kaposi's sarcoma-associated herpesvirus (KSHV). Preferably, the cell line is a body cavity-based lymphoma cell line, and more preferably, the cell line does not harbor Epstein-Barr virus. Two cell lines designated BC-2 and BC-3 are thus provided. These cell lines can be used in a method of propagating KSHV. The method comprises culturing the cell line, wherein the KSHV within the cell line thereby propagates. The BC-3 cell line, in particular, can be used in a method of propagating KSHV in the absence of Epstein-Barr virus. The method comprises culturing the cell line designated BC-3, wherein the KSHV within the cell line thereby propagates. Further provided is a purified viral suspension of KSHV, as well as a composition comprising purified KSHV and a suitable carrier.
A cell line comprising Kaposi's sarcoma-associated herpesvirus, wherein the cell line is designated BC-2 and is deposited with the ATCC as Accession No. CRL 2231.
A cell line comprising Kaposi's sarcoma-associated herpesvirus, wherein an Epstein-Barr virus is not present in the cell line and wherein the cell line is designated BC-3 and is deposited with the ATCC as Accession No. CRL 2277.
Dependencies are inferred from the claim text.